Findings
The most promising aspects of mental health for digital measurement are sleep, physical activity, stress, and social behavior, which have the strongest scientific evidence. Core barriers to adoption include high cost and limited access, data privacy concerns, poor technological literacy, and a lack of technology adaptation for specific mental health needs. Essential technology characteristics for "fit-for-purpose" sDHTs include usability, reliable performance, strong data privacy and security, and long battery life.

Recommendations
Research and development should prioritize moving promising measures (sleep, activity, stress, social behavior) to large-scale clinical trials. Algorithms must be refined and clinically validated for mental health indications, and new sensor modalities should be explored. Infrastructure must be developed by creating standards and ontologies for mental health sensor data to ensure interoperability and scalability. To improve access and equity, financial support mechanisms and inclusive, culturally tailored design are critical.

Regulatory Considerations
The report does not provide a separate section for "Regulatory Considerations" but emphasizes that future development and funding should prioritize clinical validation across diverse populations. It notes the importance of a clear understanding of the intended measurement claims and the need for rigorous validation studies to move beyond pilot and feasibility stages to demonstrate real-world clinical utility.

Findings
Misclassification of wakefulness during sleep periods and issues with tracking outside main sleep bouts.
Bias in performance evaluation studies due to limited representation of diverse populations.
Hidden complexities in consumer-grade devices related to data access, fees, privacy, and security.

Recommendations
Carefully interpret study results based on wearable sleep-tracking technology data.
Address biases in study populations by including diverse cohorts.
Ensure proper preprocessing of data from consumer-grade devices.
Avoid inserting personally identifiable information in device settings.
Evaluate issues related to specific populations like minors.

Regulatory Considerations
Complexity of privacy laws across different countries.
Need for strategies to protect personal information in device settings.
Consideration of specific population issues, such as minors, in regulatory frameworks.

Findings
The adoption of BYOD in clinical trials has been accelerated by the COVID-19 pandemic and supportive regulatory guidance, which now recognize it as an acceptable means for remote data collection. Studies have shown high measure completion and equivalent data quality between provisioned devices and BYOD, supporting its use in diverse patient populations. Key challenges to BYOD implementation include ensuring data equivalence across a wide variety of personal devices, managing participant technical support, and addressing data privacy and security concerns. The choice between native apps and web-based solutions involves trade-offs in usability, data security, and operational complexity.

Recommendations
Sponsors should develop a clear BYOD strategy that considers the target patient population, the complexity of the required data collection, and the global regulatory landscape. A robust training and support plan is essential for both participants and site staff to ensure proper device use and troubleshooting. Sponsors should work with technology vendors to ensure their platforms are user-friendly, secure, and capable of handling data from a variety of devices. It is crucial to establish clear communication channels for participants to report technical issues and receive timely assistance.

Regulatory Considerations
Both the FDA and EMA have issued guidance that supports the use of BYOD in clinical trials, provided that data integrity, security, and privacy are maintained. Sponsors must be able to demonstrate the equivalence of data collected via BYOD with data from provisioned devices. All BYOD solutions must comply with relevant data protection regulations, such as GDPR and HIPAA. The regulatory submission should include a clear description of the BYOD strategy and a justification for its use in the trial.

Findings
Despite progress, DHTs are not yet fully accepted in clinical research.
Challenges include small study samples, unrepresentative samples, lack of normative data sets, feature selection bias, and replication issues due to sensor variability.
There is a need for a framework to identify and mitigate sources of variability in DHTs.

Recommendations
Develop a conceptual framework to identify and mitigate sources of variability.
Consider both active and passive monitoring approaches in study designs.
Align knowledge and data sharing across consortia to improve DHTs.
Emphasize normative data sets to establish ground truths for variability.
Encourage precompetitive collaborations to advance regulatory maturity.

Regulatory Considerations
Collaborative efforts like the 3DT project are essential for regulatory maturity.
Global regulatory agencies encourage data-driven engagement through consortia.

Findings
The probability of receiving an irregular pulse notification was low, indicating a gap in detection sensitivity.
The study was not designed to assess the algorithm as a screening tool, highlighting a need for further research in this area.
The paroxysmal nature of atrial fibrillation presents challenges in interpreting notifications, suggesting a gap in understanding the condition's episodic nature.

Recommendations
Conduct further research to understand the implications of irregular pulse notifications.
Explore the potential for digital health technologies to engage users with healthcare systems.
Investigate the use of smartwatches and similar devices as population screening tools.
Develop methods to improve the accuracy and reliability of health monitoring algorithms.
Enhance user engagement and follow-up after receiving health notifications.

Regulatory Considerations
Ensure data privacy and consent in large-scale digital health studies.
Address the accuracy and reliability of health monitoring algorithms.
Consider the implications of using consumer-owned devices for health monitoring.

Findings
Researchers face challenges in scientific methodology, regulatory, legal, and operational aspects.
Many consumer-grade devices lack scientific evidence for their health claims.
There are significant challenges in data management, infrastructure, analysis, and security.
Lack of mobile technology data standards and transparency in data processing algorithms.
The need for a shared understanding of methodologies and terminology.

Recommendations
Develop industry-wide standards for data and terminology.
Foster dialogue between biopharmaceutical industry and device manufacturers for methodological development.
Ensure a patient-centric approach in clinical trials using wearable devices.
Conduct well-powered studies with clear medical problem statements.
Implement rigorous analytical and clinical validation processes.

Regulatory Considerations
Separate marketing approval paths for drugs and devices in the US.
Most wearable devices are classified as Class II devices requiring 510(k) clearance.
Compliance with HIPAA for data obtained via medical devices.
Need for device performance validation in specific populations relevant to device label claims.
Differences in US and EU regulations regarding data protection and consent requirements.